Cita APA

Perez-Fidalgo, J., Criscitiello, C., Carrasco, E., Regan, M., Di Leo, A., Ribi, K., . . . Bedard, P. (2022). A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.

Citación estilo Chicago

Perez-Fidalgo, JA, C. Criscitiello, E. Carrasco, MM Regan, A. Di Leo, K. Ribi, V. Adam, y PL Bedard. A Phase III Trial of Alpelisib + trastuzumab ± fulvestrant Versus Trastuzumab + Chemotherapy in HER2+ PIK3CA-mutated Breast Cancer. 2022.

Cita MLA

Perez-Fidalgo, JA, et al. A Phase III Trial of Alpelisib + trastuzumab ± fulvestrant Versus Trastuzumab + Chemotherapy in HER2+ PIK3CA-mutated Breast Cancer. 2022.